News

The Sciclone G3 combines the flexibility of its predecessors with tube-to-plate reformatting technology, non-contact liquid level and clog detection, and advanced blood tube management, in an easy-to-use software

CM-AT is based on research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of

rFIXFc is a fully-recombinant clotting factor developed using Biogen Idec’s proprietary monomeric Fc-fusion technology. In the B-Long trial, rFIXFc’s ability to prevent bleeding using different dosing regimens will

Sean Scott, senior vice president of commercial operations at Ingenuity Systems, said: “Ingenuity is excited to partner with SeouLin Bioscience – they are a recognized leader in Korea

The company said that the drug is designated as a Class III New Medicine with approximately at least four-year market exclusivity protection, upon marketing clearance by the China

The company claims that Virsani kills viruses, bacteria, and other pathogens on hands and surfaces and is available in a small aerosol can suitable for mobile personal hygiene.

As per the agreement, Penwest is expected to receive undisclosed fees and payments from Otsuka. Jennifer Good, president and CEO of Penwest, said: “We are very pleased to

However, no safety concerns were raised. As a result of the DSMB findings and recommendation, the company has decided to discontinue the study. Liplong is a randomized, double-blind

The allowed claims relate to human microRNA miR-21, a microRNA that is a potential target for a number of therapeutic indications. Regulus has access to the Tuschl III